Putting OAC therapy on hold does have its own benefits, the authors wrote, but uninterrupted OAC therapy is still the better choice.
Abbott is currently seeking a similar approval from the FDA.
The solution’s approval was based on 30-day and six-month data from a clinical study focused on mortality and hemodynamic function.
STEMI mortality remains a primary concern among healthcare providers, and a new study in the American Journal of Cardiology suggests that long-term outcomes are much better if the patient undergoes primary PCI.
The analysis included eight consecutive pediatric patients who underwent TMVR with the Sapien S3 valve. The median patient age was 9 years old.
The new study, published by the American Journal of Cardiology, suggests that frailty could be a helpful predictor for major bleeding events after PCI.
After two years, TAVR was still linked to a reduction in the study’s primary endpoint, but it was also associated with a greater risk of valve thrombosis.
The study's authors reviewed data from more than 1.8 million patients, confirming that PCI is still safe and effective when a patient has cancer.
According to new data from the ongoing COMMENCE clinical trial, patients showed no signs of structural valve deterioration after five years.
Overall, researchers wrote in the Journal of the American College of Cardiology, the PASCAL repair system has been working as it was intended.
For patients undergoing PCI, subclinical hypothyroidism was associated with higher short-term and long-term mortality.
Knowing when same-day discharge is the right choice—and when it isn’t—can be especially challenging for cardiologists and their care teams.